Moderna makes cancer breakthrough
Moderna and Merck have launched a customized vaccine based on mRNA technology to treat melanoma skin cancer. The goal is to prevent the recurrence and spread of metastases. The therapy uses an analysis of each patient’s unique tumor characteristics to produce a personalized vaccine that is injected into the muscle, encouraging the immune system to target the cancer cells. The study achieved positive results in enhancing the immune response, and this technology is expected to be integrated later for treating other types of cancers, potentially making it a fundamental tool in personalized oncology.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)